SCHEMBL503348

SCHEMBL503348

O=C(O)CSC(SCC(=O)O)C(SCC(=O)O)SCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.50
CYP2D6 P10635 2/20 0.50
HIF1A Q16665 1/20 0.50
ALKBH5 Q6P6C2 2/20 0.41
PHGDH O43175 1/20 0.38
FFAR1 O14842 1/20 0.35
LMNA P02545 2/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
BHMT Q93088 1/20 0.33
LDHA P00338 1/20 0.33
SRR Q9GZT4 1/20 0.33
TSHR P16473 1/20 0.33
SUCNR1 Q9BXA5 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
CDC25B P30305 1/20 0.33
HSD17B10 Q99714 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GMNN O75496 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ritiometan SCHEMBL867253 0.83 CYP2C19 (0.53) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL8030361 0.75 CYP2D6 (0.45) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL589940 0.75
SCHEMBL4655762 0.75
SCHEMBL9811047 0.73
SCHEMBL23931412 0.71 BHMT (0.42) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL9619629 0.71
SCHEMBL8998014 0.71 CYP2D6 (0.41) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL2808412 0.71 BHMT (0.42) CYP2C19CYP2D6HIF1AALKBH5PHGDH
SCHEMBL28862415 0.71 CYP2D6 (0.41) CYP2C19CYP2D6HIF1AALKBH5PHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113563759-A Graphene and nano-silver composite material and preparation method thereof 中国科学院山西煤炭化学研究所 2021-10-29 CN claimed
US-8569197-B2 Process for preparing a reforming catalyst comprising a support, a group VIIIB metal and a group VIIB metal IFP Energies Nouvelles (FR) 2013-10-29 US claimed
EP-2222399-B1 METHOD FOR PREPARING A REFORMING CATALYST INCLUDING A SUBSTRATE, A METAL OF GROUP VIII AND A METAL OF GROUP VIIB IFP Energies Nouvelles (FR) 2013-09-18 EP claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
US-20090143224-A1 PROCESS FOR PREPARING A REFORMING CATALYST COMPRISING A SUPPORT, A GROUP VIIIB METAL AND A GROUP VIIB METAL IFP (FR) 2009-06-04 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20240218141-A1 ORGANIC POLYMER AEROGELS COMPRISING MICROSTRUCTURES Blueshift Materials, Inc. 2024-07-04 US disclosed
EP-3529301-B1 FIBER-REINFORCED ORGANIC POLYMER AEROGEL BLUESHIFT MAT INC (US) 2023-11-29 EP disclosed
US-11814497-B2 Organic polymer aerogels comprising microstructures Blueshift Materials, Inc. (US) 2023-11-14 US disclosed
US-11345792-B2 Fiber-reinforced organic polymer aerogel Blueshift Materials, Inc. (US) 2022-05-31 US disclosed
US-11192993-B2 Organic polymer aerogels comprising microstructures Blueshift Materials, Inc. (US) 2021-12-07 US disclosed
EP-3405517-B1 ORGANIC POLYMER AEROGELS COMPRISING MICROSTRUCTURES BLUESHIFT MAT INC (US) 2021-11-10 EP disclosed
US-5413924-A For use in various in vitro chemical, biochemical and immunological reactions KOSAK KENNETH M (US) 1995-05-09 US disclosed
EP-0626017-A1 HEAT-RELEASABLE REAGENTS FOR $i(IN VITRO) CHEMICAL REACTIONS KOSAK, Kenneth M. (US) 1994-11-30 EP disclosed
EP-0617325-A1 Method of processing originating photographic elements containing tabular silver chloride grains bounded by (100) faces EASTMAN KODAK COMPANY (US) 1994-09-28 EP disclosed
WO-1993016200-A1 HEAT-RELEASABLE REAGENTS FOR IN VITRO CHEMICAL REACTIONS KOSAK KENNETH M (US) 1993-08-19 WO disclosed
US-4454224-A CONTAINING PEROXY COMPOUND, BUFFER, AND POLYACETIC ACID EASTMAN KODAK COMPANY (US) 1984-06-12 US disclosed
US-4015057-A WITH AN ALIPHATIC CARBOXYLIC ACID E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 CYP2C19 1490/4885CYP2D6 1222/4885HIF1A 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.